Compare JPMorgan Chase & Co (JPM) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Stryker Corporation — how do they compare? JPMorgan Chase & Co trades at $342.22 (market cap $900.78B), while Stryker Corporation trades at $315.49 (market cap $122.35B). The key difference: JPMorgan Chase & Co is far larger — about 7.4× Stryker Corporation's market cap, and JPMorgan Chase & Co pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| JPM | SYK | |
|---|---|---|
Market Cap | $900.78B | $122.35B |
Volume | 10,479,943 | — |
Sector | Financials | Technology |
52-Week High | $346.91 | $403.53 |
52-Week Low | $282.84 | $282.58 |
Dividend Yield | 1.77% | 1% |
Enterprise Value | — | $134.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $342.57, up 0.43% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.52 and net income margin of 33.4%, though Q4 2025 EPS missed expectations. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings, with analyst consensus leaning bullish.
JPM offers upside to the $372.73 consensus price target, driven by earnings beats and sector resilience, but faces risks from geopolitical tensions, cybersecurity threats, and volatile cash flows. Investors should weigh solid profitability against macroeconomic headwinds highlighted in recent shareholder communications.
Stryker (SYK) trades at $319.14, down 0.23% on the day, with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust profitability with 63.83% gross margins and 13.21% net margins. Recent Q1 2026 earnings missed expectations due to a cybersecurity disruption, but management maintained full-year guidance. Analyst consensus remains strongly bullish with a $388.44 price target and 74% buy ratings.
The stock presents a compelling opportunity for long-term investors given its strong fundamentals and innovation pipeline, though near-term technical weakness and competitive pressures warrant caution. Upside potential exists from continued Mako robotics adoption and market share gains, while risks include cybersecurity vulnerabilities and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
